51 Gupta S, Jain S, Brahmachari S K, et al. Pharmacogenomics: a path to predictive medicine for schizophrenia. Pharmacogenomics, 2006, 7: 31-47？？
[2]
1 Geyer M A. Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotox Res, 2008, 14: 71-78？？
[3]
2 Insel T R. Rethinking schizophrenia. Nature, 2010, 468: 187-193？？
[4]
3 Albani S, Prakken B. The advancement of translational medicine-from regional challenges to global solutions. Nat Med, 2009, 15: 1006-1009？？
[5]
4 Marincola F M. Translational medicine: a two-way road. J Transl Med, 2003, 1: 1？？
[6]
5 Milne C P, Kaitin K I. Translational medicine: an engine of change for bringing new technology to community health. Sci Transl Med, 2009, 1: 1-4
[7]
6 Wang P S, Heinssen R, Oliveri M, et al. Bridging bench and practice: translational research for schizophrenia and other psychotic disorders. Neuropsychopharmacology, 2009, 34: 204-212？？
[8]
7 Yue W H, Wang H F, Sun L D, et al. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet, 2011, 43: 1228-1231
[9]
8 Shi Y, Li Z, Xu Q, et al. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat Genet, 2011, 43: 1224-1227
[10]
9 Ma L, Tang J, Wang D, et al. Evaluating risk loci for schizophrenia distilled from genome-wide association studies in Han Chinese from central China. Mol Psychiatry, 2012, doi: 10.1038/mp.2012.63
[11]
10 Werry J S. Child and adolescent (early onset) schizophrenia: a review in light of DSM-III-R. J Autism Dev Disord, 1992, 22: 601-624？？
[12]
11 Oertel-Knochel V, Bittner R A, Knochel C, et al. Discovery and development of integrative biological markers for schizophrenia. Prog Neurobiol, 2011, 95: 686-702？？
[13]
12 Domenici E, Wille D R, Tozzi F, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One, 2010, 5: e9166？？
[14]
13 Stober G, Ben-Shachar D, Cardon M, et al. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry, 2009, 10: 127-155？？
[15]
14 Zhang X Y, Xiu M H, Song C, et al. Increased serum S100B in never-medicated and medicated schizophrenic patients. J Psychiatr Res, 2010, 44: 1236-1240？？
[16]
15 Chen da C, Wang J, Wang B, et al. Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl), 2009, 207: 375-380？？
[17]
16 Li X F, Zheng Y L, Xiu M H, et al. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 2011, 35: 1064-1067？？
[18]
17 Xiong P, Zeng Y, Zhu Z, et al. Reduced NGF serum levels and abnormal P300 event-related potential in first episode schizophrenia. Schizophr Res, 2010, 119: 34-39？？
[19]
18 Xiong P, Zeng Y, Wan J, et al. The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia. Psychiatry Res, 2011, 189: 72-76？？
[20]
19 Kaddurah-Daouk R, Soares J C, Quinones M P. Metabolomics: a global biochemical approach to the discovery of biomarkers for psychiatric disorders. In: Turck C, ed. Biomarkers for Psychiatric Disorders. New York: Springer, 2009. 1-34
[21]
20 Subashini R, Deepa M, Padmavati R, et al. Prevalence of diabetes, obesity, and metabolic syndrome in subjects with and without schizophrenia (CURES-104). J Postgrad Med, 2011, 57: 272-277
[22]
21 Van Lieshout R J, Voruganti L P. Diabetes mellitus during pregnancy and increased risk of schizophrenia in offspring: a review of the evidence and putative mechanisms. J Psychiatry Neurosci, 2008, 33: 395-404
[23]
22 Nilsson B M, Forslund A H, Olsson R M, et al. Differences in resting energy expenditure and body composition between patients with schizophrenia and healthy controls. Acta Psychiatr Scand, 2006, 114: 27-35？？
[24]
23 Nilsson B M, Olsson R M, Oman A, et al. Physical capacity, respiratory quotient and energy expenditure during exercise in male patients with schizophrenia compared with healthy controls. Eur Psychiatry, 2012, 27: 206-212？？
[25]
24 Khaitovich P, Lockstone H E, Wayland M T, et al. Metabolic changes in schizophrenia and human brain evolution. Genome Biol, 2008, 9: R124？？
[26]
25 Prabakaran S, Swatton J E, Ryan M M, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry, 2004, 9: 684-697, 643
[27]
26 Yang J, Chen T, Sun L, et al. Potential metabolite markers of schizophrenia. Mol Psychiatry, 2013, 18: 67-78？？
[28]
27 Lazarou J, Pomeranz B H, Corey P N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 1998, 279: 1200-1205？？
[29]
28 Liggett S B. Pharmacogenetic applications of the Human Genome Project. Nat Med, 2001, 7: 281-283？？
[30]
29 Couzin J. To what extent are genetic variation and personal health linked? Science, 2005, 309: 81
[31]
30 Vladutiu G D. The FDA announces new drug labeling for pharmacogenetic testing: is personalized medicine becoming a reality? Mol Genet Metab, 2008, 93: 1-4
[32]
31 Lehman A F, Lieberman J A, Dixon L B, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry, 2004, 161: 1-56？？
[33]
32 Arranz M J, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry, 2007, 12: 707-747？？
[34]
33 Zerhouni E. Medicine. The NIH Roadmap. Science, 2003, 302: 63-72？？
[35]
34 Wang L, Fang C, Zhang A, et al. The -1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol, 2008, 22: 904-909？？
[36]
35 Gu B, Wang L, Zhang A P, et al. Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. Pharmacogenet Genomics, 2008, 18: 721-727？？
[37]
36 Wei Z, Wang L, Xuan J, et al. Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry, 2009, 33: 547-551？？
[38]
37 Xing Q, Qian X, Li H, et al. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol, 2007, 10: 631-637
[39]
38 Wei Z, Wang L, Zhang M, et al. A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients. J Psychopharmacol, 2012, 26: 813-818？？
[40]
39 Wang L, Yu L, He G, et al. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci Lett, 2007, 414: 1-4？？
[41]
40 Zhang A, Xing Q, Wang L, et al. Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study. Pharmacogenomics, 2007, 8: 1337-1345？？
[42]
41 Wang L, Yu L, Zhang A P, et al. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol, 2007, 21: 837-842
[43]
42 Du J, Zhang A, Wang L, et al. Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. J Psychopharmacol, 2010, 24: 1115-1120
[44]
43 Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry, 2004, 9: 442-473？？
[45]
44 Evans W E, Relling M V. Moving towards individualized medicine with pharmacogenomics. Nature, 2004, 429: 464-468？？
[46]
45 Ritchie M D, Haas D W, Motsinger A A, et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis, 2006, 43: 779-782？？
[47]
46 Ritchie M D, Motsinger A A. Multifactor dimensionality reduction for detecting gene-gene and gene-environment interactions in pharmacogenomics studies. Pharmacogenomics, 2005, 6: 823-834？？
[48]
47 Leathart J B, London S J, Steward A, et al. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics, 1998, 8: 529-541？？
[49]
48 Masimirembwa C M, Hasler J A. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants. Brain Res Bull, 1997, 44: 561-571？？
[50]
49 Walker E, Kestler L, Bollini A, et al. Schizophrenia: etiology and course. Annu Rev Psychol, 2004, 55: 401-430？？
[51]
50 Foster A, Miller D D, Buckley P. Pharmacogenetics and schizophrenia. Clin Lab Med, 2010, 30: 975-993？？
